In ccRCC, anti-VEGF receptor tyrosine kinase inhibitors (VEGFR-TKIs) promote the development of CAFs, which in turn enhance tumor aggressiveness, metastatic potential, and resistance to therapies. Here, VEGFA is linked to neoplasm.